Due to the lack of strong evidence in terms of the benefits of prophylactic total gastrectomy (PTG) in the absence of a clear potential gastric cancer (GC) risk, these patients were followed up in accordance with the latest IGCLC recommendations.7 For breast surveillance, we suggested annual breast magnetic resonance imaging and mammography, 6-month breast ultrasonography, and annual physical examination for all 15 CDH1 variant carriers.1 With 1 exception, no patients developed DGC during a median of 5.24 years (IQR, 4.93-5.67 years) of follow-up. This evidence concerns the gene CDH1 and gastric cancer.